Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 15, Issue 1, Pages -Publisher
CUREUS INC
DOI: 10.7759/cureus.34093
Keywords
immune hemolytic anemia; morbidity and mortality; bone marrow failure; acquired aplastic anemia; paroxysmal nocturnal hemoglobinuria (pnh)
Categories
Ask authors/readers for more resources
Paroxysmal nocturnal hemoglobinuria (PNH) is a acquired X-linked, clonal hematopoietic stem cell disease with vague symptomatology, which poses difficulties in diagnosis, especially when coexisting with other hematologic disorders. The authors encourage screening for PNH clones in patients initially diagnosed with aplastic anemia (AA), treating underlying hematologic disease to prevent clonal expansion, and further research on the effectiveness of eculizumab in an unusual classical PNH secondary to AA with hypercellular bone marrow.
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired X-linked, clonal hematopoietic stem cell disease. Patients with PNH may complain of vague symptomatology that contributes to the challenge of its diagnosis. This is especially true in the clinical context of a coinciding hematologic disorder. Aplastic anemia (AA) is an additional immune-mediated illness that results in the destruction of hematopoietic precursors and pancytopenia. The authors encourage screening for PNH clones in patients initially diagnosed with AA, treating underlying hematologic disease to prevent clonal expansion, and further research to investigate the effectiveness of eculizumab in an unusual classical PNH secondary to AA with hypercellular bone marrow.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available